In vitro and preclinical assessment of an intranasal spray formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis
Osteoporosis treatment with PTH 1-34 injections significantly reduces the incidence of bone fracture. Potential further reductions in fracture rate should be observed through nasal spray delivery to address the poor compliance associated with patient dislike of repeated PTH 1-34 subcutaneous injecti...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Elsevier
2017
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/47418/ |
| _version_ | 1848797542114918400 |
|---|---|
| author | Williams, Allan J. Jordan, Faron King, Gareth Lewis, Andrew L. Illum, Lisbeth Masud, Tahir Perkins, Alan C. Pearson, Richard G. |
| author_facet | Williams, Allan J. Jordan, Faron King, Gareth Lewis, Andrew L. Illum, Lisbeth Masud, Tahir Perkins, Alan C. Pearson, Richard G. |
| author_sort | Williams, Allan J. |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Osteoporosis treatment with PTH 1-34 injections significantly reduces the incidence of bone fracture. Potential further reductions in fracture rate should be observed through nasal spray delivery to address the poor compliance associated with patient dislike of repeated PTH 1-34 subcutaneous injections. In vitro human osteoblast-like Saos-2 cell intracellular cAMP levels were used to define PTH 1-34 nasal spray formulation bioactivity. The chemically synthesised PTH 1-34 had an EC50 of 0.76nM. Absorption enhancers polyethylene glycol (15)-hydroxystearate (Solutol® HS15), poloxamer 407, chitosan or sodium hyaluronate did not diminish the bioactivity of PTH 1-34 within an in vitro cell culture model (p>0.05). We also demonstrated the effectiveness of the transmucosal absorption enhancer Solutol® HS15 in a nasal spray formulation using a preclinical pharmacokinetic model. In Sprague-Dawley rats without the absorption enhancer the uptake of PTH 1-34 into the blood via intranasal delivery produced a Cmax of 2.1±0.5 ng/ml compared to 13.7±1.6 ng/ml with Solutol® HS15 enhancer (p=0.016) and a Cmax14.8±8 ng/ml in subcutaneous injections. Together these data illustrate that the nasal spray formulation bioactivity in vitro is not affected by the nasal spray absorption enhancers investigated, and the Solutol® HS15 nasal spray formulation had an equivalent pharmacokinetic profile to subcutaneous injection in the rat model. The Solutol® HS15 formulation therefore demonstrated potential as a PTH 1-34 nasal spray formulation for the treatment of osteoporosis. |
| first_indexed | 2025-11-14T20:05:32Z |
| format | Article |
| id | nottingham-47418 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T20:05:32Z |
| publishDate | 2017 |
| publisher | Elsevier |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-474182020-05-04T19:12:46Z https://eprints.nottingham.ac.uk/47418/ In vitro and preclinical assessment of an intranasal spray formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis Williams, Allan J. Jordan, Faron King, Gareth Lewis, Andrew L. Illum, Lisbeth Masud, Tahir Perkins, Alan C. Pearson, Richard G. Osteoporosis treatment with PTH 1-34 injections significantly reduces the incidence of bone fracture. Potential further reductions in fracture rate should be observed through nasal spray delivery to address the poor compliance associated with patient dislike of repeated PTH 1-34 subcutaneous injections. In vitro human osteoblast-like Saos-2 cell intracellular cAMP levels were used to define PTH 1-34 nasal spray formulation bioactivity. The chemically synthesised PTH 1-34 had an EC50 of 0.76nM. Absorption enhancers polyethylene glycol (15)-hydroxystearate (Solutol® HS15), poloxamer 407, chitosan or sodium hyaluronate did not diminish the bioactivity of PTH 1-34 within an in vitro cell culture model (p>0.05). We also demonstrated the effectiveness of the transmucosal absorption enhancer Solutol® HS15 in a nasal spray formulation using a preclinical pharmacokinetic model. In Sprague-Dawley rats without the absorption enhancer the uptake of PTH 1-34 into the blood via intranasal delivery produced a Cmax of 2.1±0.5 ng/ml compared to 13.7±1.6 ng/ml with Solutol® HS15 enhancer (p=0.016) and a Cmax14.8±8 ng/ml in subcutaneous injections. Together these data illustrate that the nasal spray formulation bioactivity in vitro is not affected by the nasal spray absorption enhancers investigated, and the Solutol® HS15 nasal spray formulation had an equivalent pharmacokinetic profile to subcutaneous injection in the rat model. The Solutol® HS15 formulation therefore demonstrated potential as a PTH 1-34 nasal spray formulation for the treatment of osteoporosis. Elsevier 2017-10-14 Article PeerReviewed Williams, Allan J., Jordan, Faron, King, Gareth, Lewis, Andrew L., Illum, Lisbeth, Masud, Tahir, Perkins, Alan C. and Pearson, Richard G. (2017) In vitro and preclinical assessment of an intranasal spray formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis. International Journal of Pharmaceutics . ISSN 1873-3476 Osteoporosis teriparatide formulation nasal spray osteoblast drug delivery http://www.sciencedirect.com/science/article/pii/S0378517317309997 doi:10.1016/j.ijpharm.2017.10.029 doi:10.1016/j.ijpharm.2017.10.029 |
| spellingShingle | Osteoporosis teriparatide formulation nasal spray osteoblast drug delivery Williams, Allan J. Jordan, Faron King, Gareth Lewis, Andrew L. Illum, Lisbeth Masud, Tahir Perkins, Alan C. Pearson, Richard G. In vitro and preclinical assessment of an intranasal spray formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis |
| title | In vitro and preclinical assessment of an intranasal spray
formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis |
| title_full | In vitro and preclinical assessment of an intranasal spray
formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis |
| title_fullStr | In vitro and preclinical assessment of an intranasal spray
formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis |
| title_full_unstemmed | In vitro and preclinical assessment of an intranasal spray
formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis |
| title_short | In vitro and preclinical assessment of an intranasal spray
formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis |
| title_sort | in vitro and preclinical assessment of an intranasal spray
formulation of parathyroid hormone pth 1-34 for the treatment of osteoporosis |
| topic | Osteoporosis teriparatide formulation nasal spray osteoblast drug delivery |
| url | https://eprints.nottingham.ac.uk/47418/ https://eprints.nottingham.ac.uk/47418/ https://eprints.nottingham.ac.uk/47418/ |